English  |  正體中文  |  简体中文  |  0  
???header.visitor??? :  51824383    ???header.onlineuser??? :  778
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

"zhong zhe lin"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 1-50 of 125  (3 Page(s) Totally)
1 2 3 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2022-06-10T06:11:17Z Combination of 13-cis retinoic acid and interferon-�\ in the treatment of recurrent or refractory peripheral T-cell lymphoma Huang C.-L.; ZHONG-ZHE LIN; Su I.-J.; Chao T.-Y.; Tien H.-F.; Chang M.-C.; Huang M.-C.; Kao W.-Y.; Tang J.-L.; Yeh K.-H.; Wang C.-H.; Hsu C.-H.; Liu M.-Y.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:16Z Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment ZHONG-ZHE LIN; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H.
臺大學術典藏 2022-06-10T06:11:16Z Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma Lu Y.-S.; Kashida Y.; Kulp S.K.; Wang Y.-C.; Wang D.; Hung J.-H.; Tang M.; ZHONG-ZHE LIN; Chen T.-J.; Cheng A.-L.; Chen C.-S.
臺大學術典藏 2022-06-10T06:11:15Z High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy Perng R.-P.; Yang C.-H.; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; Yu C.-J.; Chang W.-C.; Kuo H.-P.; Yu C.-T.; ZHONG-ZHE LIN; Kao W.-Y.
臺大學術典藏 2022-06-10T06:11:15Z Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy Yang C.-H.; Yu C.-J.; Shih J.-Y.; Chang Y.-C.; Hu F.-C.; Tsai M.-C.; Chen K.-Y.; ZHONG-ZHE LIN; Huang C.-J.; Shun C.-T.; Huang C.-L.; Bean J.; Cheng A.-L.; Pao W.; Yang P.-C.
臺大學術典藏 2022-06-10T06:11:15Z Sunitinib-induced myxedema coma Chen S.-Y.; Kao P.-C.; ZHONG-ZHE LIN; Chiang W.-C.; Fang C.-C.
臺大學術典藏 2022-06-10T06:11:14Z The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma ZHONG-ZHE LIN; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; Kuo S.-H.; Hsu C.; Hu F.-C.; Jeng Y.-M.; Chung Y.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:14Z Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment Shao Y.-Y.; ZHONG-ZHE LIN; Liang P.-C.; Tien Y.-W.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:14Z Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival Shen Y.-C.; Hu F.-C.; Jeng Y.-M.; Chang Y.-T.; ZHONG-ZHE LIN; Chang M.-C.; Hsu C.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:13Z A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting Ho C.-L.; Su W.-C.; Hsieh R.-K.; ZHONG-ZHE LIN; Chao T.-Y.
臺大學術典藏 2022-06-10T06:11:13Z Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma Yang S.-H.; ZHONG-ZHE LIN; Kuo S.-H.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:13Z Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma Hsu C.-H.; Shen Y.-C.; ZHONG-ZHE LIN; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:13Z EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment Huang C.-L.; Yang C.-H.; Yeh K.-H.; Hu F.-C.; Chen K.-Y.; Shih J.-Y.; ZHONG-ZHE LIN; Yu C.-J.; Cheng A.-L.; Yang P.-C.
臺大學術典藏 2022-06-10T06:11:12Z Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; ZHONG-ZHE LIN; Chao T.-Y.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:12Z Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors Lin C.-C.; Hsu H.-H.; Sun C.-T.; Shih J.-Y.; ZHONG-ZHE LIN; Yu C.-J.; Chen G.G.; Hsin M.K.Y.; Lam K.C.; Leung L.; Yang C.-H.; Mok T.
臺大學術典藏 2022-06-10T06:11:12Z Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma Shao Y.; Huang C.; Liang P.; ZHONG-ZHE LIN
臺大學術典藏 2022-06-10T06:11:11Z Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma Shao Y.-Y.; ZHONG-ZHE LIN; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:11Z Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC ZHONG-ZHE LIN; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Tsao H.-W.; Lai P.; Lee P.; Cheng A.-L.; Hsu H.-C.
臺大學術典藏 2022-06-10T06:11:10Z A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor Yang S.-H.; Lin C.-C.; ZHONG-ZHE LIN; Tseng Y.-L.; Hong R.-L.
臺大學術典藏 2022-06-10T06:11:10Z High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy Shao Y.-Y.; ZHONG-ZHE LIN; Chen T.-J.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:10Z Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma Shao Y.U.-Y.; Chen P.-J.; ZHONG-ZHE LIN; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:09Z Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma Shao Y.-Y.; ZHONG-ZHE LIN; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:09Z Survival of patients with small cell lung carcinoma in Taiwan Kuo Y.-H.; ZHONG-ZHE LIN; Yang Y.-Y.; Shao Y.-Y.; Shau W.-Y.; Kuo R.N.C.; Yang J.C.-H.; Lai M.-S.
臺大學術典藏 2022-06-10T06:11:08Z Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: An East Asian population-based study ZHONG-ZHE LIN; Shau W.-Y.; Shao Y.-Y.; Yang Y.-Y.; Kuo R.N.-C.; Yang J.C.-H.; Laie M.-S.
臺大學術典藏 2022-06-10T06:11:08Z The impact of diabetes mellitus on prognosis of early breast cancer in Asia Chen W.-W.; Shao Y.-Y.; Shau W.-Y.; ZHONG-ZHE LIN; Lu Y.-S.; Chen H.-M.; Kuo R.N.C.; Cheng A.-L.; Lai M.-S.
臺大學術典藏 2022-06-10T06:11:08Z Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma Shau W.-Y.; Shao Y.-Y.; Yeh Y.-C.; ZHONG-ZHE LIN; Kuo R.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lai M.-S.
臺大學術典藏 2022-06-10T06:11:08Z Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy ZHONG-ZHE LIN; Hsu C.; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L.
臺大學術典藏 2022-06-10T06:11:07Z Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems Shao Y.-Y.; Lu L.-C.; ZHONG-ZHE LIN; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:07Z Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer Shao Y.-Y.; Shau W.-Y.; ZHONG-ZHE LIN; Chen H.-M.; Kuo R.; Yang J.C.-H.; Lai M.-S.
臺大學術典藏 2022-06-10T06:11:06Z Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma Lu L.-C.; Shao Y.-Y.; Kuo R.N.C.; ZHONG-ZHE LIN; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏 2022-06-10T06:11:06Z The aurora kinases inhibitor VE-465 is a novel treatment for glioblastoma multiforme Lee P.-Y.; Chen C.-L.; ZHONG-ZHE LIN; Cheng A.-L.; Chen E.I.-T.; Whang-Peng J.; Huang C.-Y.F.
臺大學術典藏 2022-06-10T06:11:06Z A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; ZHONG-ZHE LIN
臺大學術典藏 2022-06-10T06:11:05Z Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size ZHONG-ZHE LIN; Shau W.-Y.; Hsu C.; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏 2022-06-10T06:11:05Z Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer Shen Y.-C.; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; ZHONG-ZHE LIN; Chen L.-T.; Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:04Z Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; ZHONG-ZHE LIN; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:04Z Type 2 diabetes mellitus is associated with increased mortality in chinese patients receiving curative surgery for colon cancer Chen K.-H.; Shao Y.-Y.; ZHONG-ZHE LIN; Yeh Y.-C.; Wen-Yi S.; Kuo R.N.; Chen H.-M.; Lai C.-L.; Yeh K.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏 2022-06-10T06:11:04Z Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption ZHONG-ZHE LIN; Chou C.-H.; Cheng A.-L.; Liu W.-L.; Chia-Hsien Cheng J.
臺大學術典藏 2022-06-10T06:11:03Z The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia Kuo H.-Y.; ZHONG-ZHE LIN; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S.
臺大學術典藏 2022-06-10T06:11:03Z Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma Liao B.-C.; Shao Y.-Y.; Chen H.-M.; Shau W.-Y.; ZHONG-ZHE LIN; Kuo R.N.; Lai C.-L.; Chen K.-H.; Cheng A.-L.; Yang J.C.-H.; Lai M.-S.
臺大學術典藏 2022-06-10T06:11:02Z Young patients with colorectal cancer have increased risk of second primary cancers Liang Y.-H.; Shao Y.-Y.; Chen H.-M.; Lai C.-L.; ZHONG-ZHE LIN; Kuo R.N.; Cheng A.-L.; Yeh K.-H.; Lai M.-S.
臺大學術典藏 2022-06-10T06:11:02Z Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan Shao Y.-Y.; Hsu C.-H.; Yeh K.-H.; Chen H.-M.; Yeh Y.-C.; Lai C.-L.; ZHONG-ZHE LIN; Cheng A.-L.; Lai M.-S.
臺大學術典藏 2022-06-10T06:11:01Z The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases Chiang Y.; Yang J.C.-H.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; ZHONG-ZHE LIN; Lan K.-H.; Cheng A.-L.; Kuo S.-H.
臺大學術典藏 2022-06-10T06:11:00Z Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study Chen K.-H.; Shao Y.-Y.; Chen H.-M.; Lin Y.-L.; ZHONG-ZHE LIN; Lai M.-S.; Cheng A.-L.; Yeh K.-H.
臺大學術典藏 2022-06-10T06:11:00Z Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; ZHONG-ZHE LIN; Lin C.-C.; Yang J.C.H.; Yu C.-J.
臺大學術典藏 2022-06-10T06:11:00Z Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC) Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; ZHONG-ZHE LIN; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A.
臺大學術典藏 2022-06-10T06:10:59Z A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T.
臺大學術典藏 2022-06-10T06:10:59Z Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy Shao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C.
臺大學術典藏 2022-06-10T06:10:58Z Considerations of heterogeneity in clinical trials for hepatocellular carcinoma Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; ZHONG-ZHE LIN; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:10:58Z Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; ZHONG-ZHE LIN; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2022-06-10T06:10:57Z Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status Chen H.-C.; Tan E.C.-H.; Liao C.-H.; ZHONG-ZHE LIN; Yang M.-C.

Showing items 1-50 of 125  (3 Page(s) Totally)
1 2 3 > >>
View [10|25|50] records per page